Infections caused by pathogens sensitive to ceftazidime/avibactam Acute or acute-on-chronic renal failure requiring continuous dialysis treatment
Conditions
Interventions
Group 1: In patients who are receiving the antibiotic ceftazidime/avibactam because of an infection and who require dialysis treatment (CVVHD) because of renal insufficiency, the plasma concentrations
Sponsors
Center of Breath ResearchKlinik für Anästhesiologie, Intensivmedizin und SchmerztherapieUniversitätsklinikum des Saarlandes
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Written consent of the patient or his/her legal guardian, patient > 18 years of age, acute renal failure with indication for continuous renal replacement therapy, patient already receiving ceftazidime/avibactam or administration is planned for medical indication, central venous catheter for taking blood samples has already been placed for medical indication , BMI < 35, for women of childbearing potential: negative pregnancy test, or previous surgical sterilization or use of contraceptives during the examination or at least 2 years after postmenopause.
Exclusion criteria
Exclusion criteria: Refusal by the patient, contraindications or known intolerance to one of the medications or procedures used, previous illnesses or patient circumstances that make an examination of the patient impossible or impractical (e.g. dementia, psychiatric diseases, lack of understanding of speech or speech), body mass index > 35 , pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma concentration course of ceftazidime/avibactam with and without multifiltration dialysis 1. before first delivery 2. 15 min after initial administration 3. 30 min after initial administration 4. 60 min after initial administration 5. 90 min after initial administration 6. 120 min after initial administration 7. 180 min after initial administration 8. 240 min after initial administration 9. 300 min after initial administration 10. 360 min after initial administration | — |
Secondary
| Measure | Time frame |
|---|---|
| change in distribution volumes and clearance values; Correlation between ceftazidime/avibactam dosage and plasma concentrations considering the cofactors: acute renal failure, multifiltration dialysis, ceftazidime/avibactam in the dialysis filtrate. The endpoints are calculated after all plasma measurements have been completed within a pharmacokinetic model. | — |
Countries
Germany
Contacts
Public ContactTobias Hüppe
Center of Breath Research,Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie,Universitätsklinikum des Saarlandes
Outcome results
None listed